I was reading Novo Nordisk’s Q3 2024 earnings report last month when something made me stop scrolling.
Not the revenue numbers—though $21 billion in annual sales from two weight loss drugs is staggering. What caught my eye was a single line buried on page 47 in the competitive landscape section: “We are monitoring oral GLP-1 formulations in clinical development.”
One sentence. No elaboration. No details.
Most analysts would skip right past it.
But I couldn’t. That footnote sent me down a research rabbit hole that’s consumed the last seven weeks—and led me to what I think is one of the most asymmetric investment opportunities in biotech today.
Let me back up and explain why that single sentence matters so much.
Before I started digging into this, I didn’t fully appreciate just how dominant Novo Nordisk has become. The company is now worth $570 billion—more valuable than Tesla, Walmart, or the entire economy of Denmark where it’s headquartered.
A pharmaceutical company that most Americans couldn’t name three years ago is now one of the ten largest companies on Earth.
The product driving this valuation? Weekly injections for weight loss.
Ozempic and Wegovy (same molecule, different branding) generated $21.1 billion in sales for Novo in 2024. Eli Lilly’s competing drugs—Mounjaro and Zepbound—added another $11.3 billion. Together, just two companies control 90% of what’s become a $54 billion market.
To put the growth in perspective: the entire GLP-1 category was worth $6 billion globally in 2020. By 2024, it hit $54 billion. Morgan Stanley projects $157 billion by 2030.
That’s faster growth than smartphones saw in their early years. We’re watching one of the most explosive pharmaceutical markets in history unfold in real time.
But the more I dug into the research—reading clinical studies, insurance claims data, physician surveys—the more an obvious problem emerged.
The drugs work extraordinarily well at producing weight loss. But patient retention is catastrophic.
I found a 2024 study published in Obesity that tracked 250,000 patients on GLP-1 medications. The discontinuation numbers stopped me cold:
Only 32% of patients still taking medication after 12 months
68% had quit before completing a full year
Top reasons: nausea/vomiting (41%), injection burden (28%), cost (22%)
This wasn’t patients giving up because the drugs failed. These were people who had lost 15-20 pounds—real, meaningful weight loss—and quit anyway because weekly self-injections plus months of severe nausea was more than they could handle.
I kept coming back to the same thought: this is a $54 billion market with a 68% annual churn rate. That’s not a business problem for Novo and Lilly—that’s a massive unmet need for whoever can solve the delivery mechanism.
Which brought me back to that footnote about oral formulations.
If Novo Nordisk—sitting on a $570 billion market cap with the best-selling obesity drug in history—is monitoring oral competition, that means someone’s building something they’re actually worried about.
So I started looking for who was working on oral versions. That’s when I found Structure Therapeutics and Viking Therapeutics.
I spent an afternoon listening to a June 2024 conference presentation by Raymond Stevens, CEO of Structure Therapeutics. He walked through their Phase 2a clinical data for GSBR-1290—an oral GLP-1 pill designed to survive stomach acid and deliver weight loss without injections.
The results caught my attention immediately:
6.2% placebo-adjusted weight loss at 12 weeks
Once-daily oral tablet (no injections)
Significantly lower rates of severe nausea vs. Ozempic
Only 5% discontinuation rate in the trial
For context: Ozempic typically shows 5-6% weight loss at 12 weeks in clinical trials before eventually reaching 15% at 68 weeks. Structure’s oral pill was tracking competitively at the same early timepoint—with dramatically better tolerability.
Then I pulled Viking Therapeutics’ Phase 2 data from August 2025. Their oral formulation, VK-2735, showed even better numbers:
10.9% placebo-adjusted weight loss at 13 weeks
Once-daily oral dosing
“Encouraging safety and tolerability profile”
Up to 100% of patients in higher-dose cohorts achieving ≥5% weight loss
Both companies reported lower discontinuation rates than current injectables. Both were advancing to larger Phase 2b or Phase 3 trials.
I kept digging—reading FDA meeting minutes, clinical trial protocols, analyst coverage from firms specializing in obesity. What became increasingly clear is that we’re approximately 18-24 months from potential FDA approvals for the first oral GLP-1 medications.
And the market hasn’t fully priced in what happens if these trials succeed.
After two weeks of analysis, I identified three structural constraints holding back the current GLP-1 market:
1. Supply bottlenecks
Both Novo Nordisk and Eli Lilly are physically unable to meet demand. They’re actively rationing doses. The companies have collectively invested over $15 billion in new manufacturing facilities—and they’re still turning patients away.
The FDA maintains active shortage listings for these drugs that haven’t cleared in 18 months. Compounding pharmacies are making unauthorized copies just to fill the gap.
2. Retention crisis
That 68% annual discontinuation rate isn’t sustainable. Patients are losing significant weight and quitting anyway because the delivery mechanism—weekly injections combined with months of severe GI side effects—is fundamentally flawed.
3. Limited market penetration
Only about 6 million Americans are currently on GLP-1 treatment. The addressable market is 110 million obese adults. That’s roughly 5% penetration despite massive demand and willingness to pay.
An oral formulation solves all three problems simultaneously:
Manufacturing scales differently. Pills don’t require the complex fermentation, purification, and cold-chain distribution that peptide biologics need. Once you’ve got the molecule working, you can manufacture oral drugs at a fraction of the cost and scale production much faster.
Retention improves dramatically. Early clinical data suggests oral GLP-1s produce 50%+ fewer severe GI side effects compared to weekly injections. Daily dosing also drives better adherence than weekly injections—it’s psychologically easier for most patients.
Market penetration expands. Remove the injection barrier and you open the market to patients who would never self-inject. That’s not a small group—injection anxiety is a real phenomenon that excludes millions of potential patients.
I started modeling the market scenarios. If an oral GLP-1 achieves even 80% of Wegovy’s efficacy (12% weight loss vs. 15%) but cuts the discontinuation rate in half (35% vs. 68%), the addressable market changes completely.
Conservative math at 20% U.S. market penetration:
22 million patients × $600/month × 12 months = $158 billion annual U.S. market alone
Add Europe and Asia, and you’re approaching $250+ billion globally
The current market is $54 billion. We’re talking about 3-5x expansion driven purely by better delivery and retention.
And three specific companies are positioned to capture it.
Over the past two weeks, I’ve built positions in the three biotechs I believe have the highest probability of bringing oral GLP-1s to market successfully. Combined, they represent about 9% of my total portfolio—my largest thematic allocation outside of AI infrastructure.
These aren’t speculative lottery tickets. These are late-stage clinical programs with published Phase 2 data, clear regulatory pathways, experienced management teams, and concrete catalysts arriving over the next 12-18 months.
One company has already enrolled Phase 3 trials and expects topline data in 2026. Another is running Phase 2b studies with results due Q4 2025. The third has the most compelling early efficacy data but carries higher execution risk.
In the rest of this analysis, I’m going to reveal:
The three specific companies I’m positioned in — tickers, current market caps, and why each one fits differently in my portfolio
Detailed clinical data breakdowns — Phase 2 efficacy numbers, safety profiles, and how they stack up against Ozempic and Wegovy at comparable timepoints
Regulatory timelines and catalyst dates — exactly when we get critical data readouts and when FDA approvals could realistically come
Valuation analysis — what these companies could be worth if trials succeed vs. what they’re trading at today (the math is compelling)
Risk factors and position sizing — what could derail the thesis, how I’m managing downside, and why I’m comfortable with 9% portfolio exposure
Why the next 12-24 months is the window — before Phase 3 data de-risks everything and institutional money piles in
This is the most compelling risk-reward I’ve found in biotech this year. The market is massive and growing exponentially. The incumbents can’t easily defend against oral competition due to the fundamental biochemistry of their peptide molecules. And the companies building the solution are trading like nobody’s paying attention.
Let me show you exactly what I found and why I’m betting nearly 10% of my portfolio on this thesis playing out.
The Three Oral GLP-1 Plays I’m Positioned In
After seven weeks of research—reading clinical trial data, listening to conference presentations, and analyzing market positioning—I’ve built positions in three companies developing oral GLP-1 medications.
Combined, they represent 9% of my portfolio. That’s my largest thematic allocation outside of AI infrastructure.
Let me walk you through each one, starting with the company that just reported Phase 2b data three weeks ago.